Growing evidence from clinical trials of the next-generation androgen receptor (AR) pathway inhibitors abiraterone acetate (AA) and MDV3100 suggests that both compounds are likely to transform the care of patients with castration-resistant prostate cancer (CRPC), and drug approvals are anticipated in the next 1 to 2 years. However, not all patients benefit from these drugs, and the durability of response in those who do respond can be short. We are focusing on two parallel strategies to achieve better clinical results: 1) developing more potent AR inhibitors, and 2) defining mechanisms of drug resistance that will guide the rational selection of combination therapies. During the current funding cycle of this project (formerly RP-6, 2008-2010), we discovered the novel antiandrogen A52, which has superior activity to MDV3100 in side-by-side comparison. We then advanced the compound (now called ARN-509) to a phase 1 clinical trial in patients with CRPC, in collaboration with a corporate partner (Aragon Pharmaceuticals). In other work, we discovered that PTEN loss (found in -40% of primary prostate cancers) confers resistance to both MDV3100 and ARN-509 in preclinical prostate cancer models, but that this resistance can be overcome by combination therapy with a dual P13K/mTOR inhibitor, BEZ235. In the proposed funding period we will conduct clinical trials that directly address 1) the role of PTEN loss as a biomarker of resistance, and 2) whether combined PI3K + next-generation AR inhibition is more active than next-generation AR inhibition alone. We will also conduct pilot studies to evaluate ARN-509 in presurgical (ie, noncastrate) patients with prostate cancer.
Aim 1 : To determine if PTEN loss confers resistance to the next-generation AR antagonist ARN-509 in an expansion cohort of patients with metastatic CRPC treated in an ongoing phase 1 clinical trial.
Aim 2 : To evaluate the activity of the dual PI3K/mT0R inhibitor BEZ235 in patients with CRPC, first alone, then in combination with abiraterone.
Aim 3 : To evaluate the effects of ARN-509 in localized, hormone-nave disease in presurgical trials
Drug development in prostate cancer has moved from the evaluation of cytotoxic agents with activity in other tumor types to the rational development of targeted approaches based on a fundamental understanding of disease biology. This approach is validated by reported results with AR signaling inhibitors targeting oncogenic changes identified in molecular profiling studies of CRPC.
|Cheal, Sarah M; Punzalan, Blesida; Doran, Michael G et al. (2014) Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino Eur J Nucl Med Mol Imaging 41:985-94|
|Bancroft, Elizabeth K; Page, Elizabeth C; Castro, Elena et al. (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66:489-99|
|Sjoberg, Daniel D (2014) Toward a Smarter Prostate Cancer Screening Program. Eur Urol :|
|Ehdaie, Behfar; Vertosick, Emily; Spaliviero, Massimiliano et al. (2014) The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 191:660-4|
|Ahmad-Tajudin, Asilah; Adler, Belinda; Ekstrom, Simon et al. (2014) MALDI-target integrated platform for affinity-captured protein digestion. Anal Chim Acta 807:1-8|
|Vickers, Andrew J (2014) Clinical trials in crisis: Four simple methodologic fixes. Clin Trials 11:615-21|
|Bryant, Richard J; Lilja, Hans (2014) Emerging PSA-based tests to improve screening. Urol Clin North Am 41:267-76|
|Vertosick, Emily A; Poon, Bing Ying; Vickers, Andrew J (2014) Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol 192:724-8|
|Vickers, Andrew J; Pepe, Margaret (2014) Does the net reclassification improvement help us evaluate models and markers? Ann Intern Med 160:136-7|
|Shi, Yuji; Wang, Junru; Chandarlapaty, Sarat et al. (2014) PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol 21:522-7|
Showing the most recent 10 out of 310 publications